{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T22:24:34Z","timestamp":1794263074080,"version":"4.9.0"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":63,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01528-5","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T13:54:54Z","timestamp":1780062894000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Monoclonal gammopathy of clinical significance: a multisystem review"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2939-5400","authenticated-orcid":false,"given":"Manraj Singh","family":"Sra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-1833","authenticated-orcid":false,"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"1528_CR1","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1182\/blood-2018-04-839480","volume":"132","author":"J-P Fermand","year":"2018","unstructured":"Fermand J-P, Bridoux F, Dispenzieri A, Jaccard A, Kyle RA, Leung N, et al. Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood. 2018;132:1478\u201385.","journal-title":"Blood"},{"key":"1528_CR2","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1182\/hematology.2020000122","volume":"2020","author":"A Dispenzieri","year":"2020","unstructured":"Dispenzieri A. Monoclonal gammopathies of clinical significance. Hematol Am Soc Hematol Educ Program. 2020;2020:380\u20138.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"1528_CR3","doi-asserted-by":"publisher","first-page":"4292","DOI":"10.1182\/blood-2012-07-445304","volume":"120","author":"N Leung","year":"2012","unstructured":"Leung N, Bridoux F, Hutchison CA, Nasr SH, Cockwell P, Fermand J-P, et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood. 2012;120:4292\u20135.","journal-title":"Blood"},{"key":"1528_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41581-018-0077-4","volume":"15","author":"N Leung","year":"2019","unstructured":"Leung N, Bridoux F, Batuman V, Chaidos A, Cockwell P, D\u2019Agati VD, et al. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol. 2019;15:45\u201359.","journal-title":"Nat Rev Nephrol"},{"key":"1528_CR5","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.2215\/CJN.02560316","volume":"11","author":"M Doshi","year":"2016","unstructured":"Doshi M, Lahoti A, Danesh FR, Batuman V, Sanders PW. American Society of Nephrology Onco-Nephrology Forum. Paraprotein-Related Kidney Disease: Kidney injury from paraproteins-what determines the site of injury? Clin J Am Soc Nephrol. 2016;11:2288\u201394.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1528_CR6","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/labinvest.3700069","volume":"84","author":"J Teng","year":"2004","unstructured":"Teng J, Russell WJ, Gu X, Cardelli J, Jones ML, Herrera GA. Different types of glomerulopathic light chains interact with mesangial cells using a common receptor but exhibit different intracellular trafficking patterns. Lab Invest. 2004;84:440\u201351.","journal-title":"Lab Invest"},{"key":"1528_CR7","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1681\/ASN.2012060577","volume":"23","author":"H Debiec","year":"2012","unstructured":"Debiec H, Hanoy M, Francois A, Guerrot D, Ferlicot S, Johanet C, et al. Recurrent membranous nephropathy in an allograft caused by IgG3\u03ba targeting the PLA2 receptor. J Am Soc Nephrol. 2012;23:1949\u201354.","journal-title":"J Am Soc Nephrol"},{"key":"1528_CR8","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.3389\/fimmu.2018.02260","volume":"9","author":"S Chauvet","year":"2018","unstructured":"Chauvet S, Roumenina LT, Aucouturier P, Marinozzi M-C, Dragon-Durey M-A, Karras A, et al. Both Monoclonal and Polyclonal Immunoglobulin Contingents Mediate Complement Activation in Monoclonal Gammopathy Associated-C3 Glomerulopathy. Front Immunol. 2018;9:2260.","journal-title":"Front Immunol"},{"key":"1528_CR9","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1007\/s11255-017-1594-y","volume":"49","author":"M Ciocchini","year":"2017","unstructured":"Ciocchini M, Arbelbide J, Musso CG. Monoclonal gammopathy of renal significance (MGRS): the characteristics and significance of a new meta-entity. Int Urol Nephrol. 2017;49:2171\u20135.","journal-title":"Int Urol Nephrol"},{"key":"1528_CR10","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.18632\/oncotarget.23412","volume":"9","author":"N Steiner","year":"2018","unstructured":"Steiner N, G\u00f6bel G, Suchecki P, Prokop W, Neuwirt H, Gunsilius E. Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma: an observational study of 2935 MGUS patients. Oncotarget. 2018;9:2344\u201356.","journal-title":"Oncotarget"},{"key":"1528_CR11","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1681\/ASN.2017121319","volume":"29","author":"S Sethi","year":"2018","unstructured":"Sethi S, Rajkumar SV, D\u2019Agati VD. The Complexity and Heterogeneity of Monoclonal Immunoglobulin-Associated Renal Diseases. J Am Soc Nephrol. 2018;29:1810\u201323.","journal-title":"J Am Soc Nephrol"},{"key":"1528_CR12","doi-asserted-by":"crossref","unstructured":"Klomjit N, Evans MD, Vargas M, Marka N, Fervenza F, Sethi S, et al. The Mayo MGRS Prediction Tool calculates the risk of finding monoclonal gammopathy of renal significance in a kidney biopsy in patients with monoclonal gammopathy. Kidney Int. 2025.","DOI":"10.1016\/j.kint.2025.04.018"},{"key":"1528_CR13","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1002\/ajh.24528","volume":"91","author":"TV Kourelis","year":"2016","unstructured":"Kourelis TV, Nasr SH, Dispenzieri A, Kumar SK, Gertz MA, Fervenza FC, et al. Outcomes of patients with renal monoclonal immunoglobulin deposition disease. Am J Hematol. 2016;91:1123\u20138.","journal-title":"Am J Hematol"},{"key":"1528_CR14","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2215\/CJN.08640811","volume":"7","author":"SH Nasr","year":"2012","unstructured":"Nasr SH, Valeri AM, Cornell LD, Fidler ME, Sethi S, D\u2019Agati VD, et al. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol. 2012;7:231\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1528_CR15","doi-asserted-by":"publisher","first-page":"122","DOI":"10.2215\/CJN.05750710","volume":"6","author":"SH Nasr","year":"2011","unstructured":"Nasr SH, Sethi S, Cornell LD, Fidler ME, Boelkins M, Fervenza FC, et al. Proliferative glomerulonephritis with monoclonal IgG deposits recurs in the allograft. Clin J Am Soc Nephrol. 2011;6:122\u201332.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1528_CR16","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.kint.2018.01.028","volume":"94","author":"SM Said","year":"2018","unstructured":"Said SM, Cosio FG, Valeri AM, Leung N, Sethi S, Salameh H, et al. Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits is associated with high rate of early recurrence in the allograft. Kidney Int. 2018;94:159\u201369.","journal-title":"Kidney Int"},{"key":"1528_CR17","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1053\/j.ajkd.2003.09.020","volume":"43","author":"N Leung","year":"2004","unstructured":"Leung N, Lager DJ, Gertz MA, Wilson K, Kanakiriya S, Fervenza FC. Long-term outcome of renal transplantation in light-chain deposition disease. Am J Kidney Dis. 2004;43:147\u201353.","journal-title":"Am J Kidney Dis"},{"key":"1528_CR18","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.3324\/haematol.2019.239632","volume":"105","author":"S R\u00f6gnvaldsson","year":"2020","unstructured":"R\u00f6gnvaldsson S, Steingr\u00edmsson V, Turesson I, Bj\u00f6rkholm M, Landgren O, Yngvi Kristinsson S. Peripheral neuropathy and monoclonal gammopathy of undetermined significance: a population-based study including 15,351 cases and 58,619 matched controls. Haematologica. 2020;105:2679\u201381.","journal-title":"Haematologica"},{"key":"1528_CR19","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1097\/01.wco.0000245368.36576.0d","volume":"19","author":"AJ Steck","year":"2006","unstructured":"Steck AJ, Stalder AK, Renaud S. Anti-myelin-associated glycoprotein neuropathy. Curr Opin Neurol. 2006;19:458\u201363.","journal-title":"Curr Opin Neurol"},{"key":"1528_CR20","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1111\/bjh.14492","volume":"176","author":"S D\u2019Sa","year":"2017","unstructured":"D\u2019Sa S, Kersten MJ, Castillo JJ, Dimopoulos M, Kastritis E, Laane E, et al. Investigation and management of IgM and Waldenstr\u00f6m-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel. Br J Haematol. 2017;176:728\u201342.","journal-title":"Br J Haematol"},{"key":"1528_CR21","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.3324\/haematol.2022.280953","volume":"107","author":"J Khwaja","year":"2022","unstructured":"Khwaja J, D\u2019Sa S, Minnema MC, Kersten MJ, Wechalekar A, Vos JM. IgM monoclonal gammopathies of clinical significance: diagnosis and management. Haematologica. 2022;107:2037\u201350 1.","journal-title":"Haematologica"},{"key":"1528_CR22","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/ajh.26155","volume":"96","author":"JJ Castillo","year":"2021","unstructured":"Castillo JJ, Callander NS, Baljevic M, Sborov DW, Kumar S. The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance. Am J Hematol. 2021;96:846\u201353.","journal-title":"Am J Hematol"},{"key":"1528_CR23","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1136\/jnnp-2017-316689","volume":"89","author":"JM Vos","year":"2018","unstructured":"Vos JM, Notermans NC, D\u2019Sa S, Lunn MP, van der Pol WL, Kraan W, et al. High prevalence of the MYD88 L265P mutation in IgM anti-MAG paraprotein-associated peripheral neuropathy. J Neurol Neurosurg Psychiatr. 2018;89:1007\u20139.","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"1528_CR24","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1182\/hematology.2024000665","volume":"2024","author":"MT Cibeira","year":"2024","unstructured":"Cibeira MT, Rodr\u00edguez-Lobato LG, Alejaldre A, Fern\u00e1ndez, de Larrea C. Neurological manifestations of MGUS. Hematol Am Soc Hematol Educ Program. 2024;2024:499\u2013504.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"1528_CR25","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.mayocp.2017.02.003","volume":"92","author":"HM Chaudhry","year":"2017","unstructured":"Chaudhry HM, Mauermann ML, Rajkumar SV. Monoclonal gammopathy-associated peripheral neuropathy: diagnosis and management. Mayo Clin Proc. 2017;92:838\u201350.","journal-title":"Mayo Clin Proc"},{"key":"1528_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11940-017-0479-9","volume":"19","author":"E Nobile-Orazio","year":"2017","unstructured":"Nobile-Orazio E, Bianco M, Nozza A. Advances in the treatment of paraproteinemic neuropathy. Curr Treat Options Neurol. 2017;19:43.","journal-title":"Curr Treat Options Neurol"},{"key":"1528_CR27","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1111\/j.1468-1331.2010.03345.x","volume":"18","author":"S Mat\u00e0","year":"2011","unstructured":"Mat\u00e0 S, Borsini W, Ambrosini S, Toscani L, Barilaro A, Piacentini S, et al. IgM monoclonal gammopathy-associated neuropathies with different IgM specificity. Eur J Neurol. 2011;18:1067\u201373.","journal-title":"Eur J Neurol"},{"key":"1528_CR28","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1212\/WNL.0000000000001047","volume":"83","author":"NC Voermans","year":"2014","unstructured":"Voermans NC, Benveniste O, Minnema MC, Lokhorst H, Lammens M, Meersseman W, et al. Sporadic late-onset nemaline myopathy with MGUS: long-term follow-up after melphalan and SCT. Neurology. 2014;83:2133\u20139.","journal-title":"Neurology"},{"key":"1528_CR29","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.nmd.2021.04.010","volume":"31","author":"W De Ridder","year":"2021","unstructured":"De Ridder W, De Jonghe P, Straub V, Baets J. High prevalence of sporadic late-onset nemaline myopathy in a cohort of whole-exome sequencing negative myopathy patients. Neuromuscul Disord. 2021;31:1154\u201360.","journal-title":"Neuromuscul Disord"},{"key":"1528_CR30","doi-asserted-by":"publisher","first-page":"103960","DOI":"10.1016\/j.autrev.2025.103960","volume":"25","author":"A Lauletta","year":"2026","unstructured":"Lauletta A, Forcina F, Merlonghi G, Fionda L, Leonardi L, Costanzo R, et al. Sporadic late-onset nemaline myopathy (SLONM): Data from a case series and literature review of 144 patients. Autoimmun Rev. 2026;25:103960.","journal-title":"Autoimmun Rev"},{"key":"1528_CR31","doi-asserted-by":"publisher","first-page":"8545","DOI":"10.1200\/JCO.2020.38.15_suppl.8545","volume":"38","author":"R Kotchetkov","year":"2020","unstructured":"Kotchetkov R, Susman D, Buadi F, Dispenzieri A. Sporadic late-onset nemaline myopathy with monoclonal paraprotein as a malignancy rather than disimmunity and treatment with chemotherapy-based approach. JCO. 2020;38:8545\u20138545.","journal-title":"JCO"},{"key":"1528_CR32","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/jdv.13847","volume":"31","author":"D Lipsker","year":"2017","unstructured":"Lipsker D. Monoclonal gammopathy of cutaneous significance: review of a relevant concept. J Eur Acad Dermatol Venereol. 2017;31:45\u201352.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1528_CR33","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/jdv.14244","volume":"31","author":"A Guarneri","year":"2017","unstructured":"Guarneri A, Cioni M, Rongioletti F. High-dose intravenous immunoglobulin therapy for scleromyxoedema: a prospective open-label clinical trial using an objective score of clinical evaluation system. J Eur Acad Dermatol Venereol. 2017;31:1157\u201360.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1528_CR34","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/acr.23908","volume":"72","author":"CA Mecoli","year":"2020","unstructured":"Mecoli CA, Talbot CC, Fava A, Cheadle C, Boin F, Wigley FM, et al. Clinical and molecular phenotyping in scleromyxedema pretreatment and posttreatment with intravenous immunoglobulin. Arthritis Care Res. 2020;72:761\u20137.","journal-title":"Arthritis Care Res"},{"key":"1528_CR35","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jaad.2013.01.028","volume":"69","author":"F Brunet-Possenti","year":"2013","unstructured":"Brunet-Possenti F, Hermine O, Marinho E, Crickx B, Descamps V. Combination of intravenous immunoglobulins and lenalidomide in the treatment of scleromyxedema. J Am Acad Dermatol. 2013;69:319\u201320.","journal-title":"J Am Acad Dermatol"},{"key":"1528_CR36","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1001\/jamadermatol.2019.4221","volume":"156","author":"CA Nelson","year":"2020","unstructured":"Nelson CA, Zhong CS, Hashemi DA, Ashchyan HJ, Brown-Joel Z, Noe MH, et al. A Multicenter Cross-Sectional Study and Systematic Review of Necrobiotic Xanthogranuloma With Proposed Diagnostic Criteria. JAMA Dermatol. 2020;156:270\u20139.","journal-title":"JAMA Dermatol"},{"key":"1528_CR37","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2165\/00128071-200203020-00005","volume":"3","author":"PR Cohen","year":"2002","unstructured":"Cohen PR, Kurzrock R. Sweet\u2019s syndrome: a review of current treatment options. Am J Clin Dermatol. 2002;3:117\u201331.","journal-title":"Am J Clin Dermatol"},{"key":"1528_CR38","doi-asserted-by":"publisher","first-page":"137","DOI":"10.5114\/pdia.2014.40974","volume":"32","author":"K Roma\u0144ska-Gocka","year":"2015","unstructured":"Roma\u0144ska-Gocka K, Cie\u015bci\u0144ska C, Zegarska B, Schwartz RA, Cie\u015bci\u0144ski J, Olszewska-S\u0142onina D, et al. Pyoderma gangrenosum with monoclonal IgA gammopathy and pulmonary tuberculosis. Illustrative case and review. Postepy Dermatol Alergol. 2015;32:137\u201341.","journal-title":"Postepy Dermatol Alergol"},{"key":"1528_CR39","doi-asserted-by":"publisher","first-page":"h2958","DOI":"10.1136\/bmj.h2958","volume":"350","author":"AD Ormerod","year":"2015","unstructured":"Ormerod AD, Thomas KS, Craig FE, Mitchell E, Greenlaw N, Norrie J, et al. Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. BMJ. 2015;350:h2958.","journal-title":"BMJ"},{"key":"1528_CR40","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/j.1365-2230.2008.02706.x","volume":"33","author":"S Cheng","year":"2008","unstructured":"Cheng S, Edmonds E, Ben-Gashir M, Yu RC. Subcorneal pustular dermatosis: 50 years on. Clin Exp Dermatol. 2008;33:229\u201333.","journal-title":"Clin Exp Dermatol"},{"key":"1528_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00661-1","volume":"12","author":"J-S Claveau","year":"2022","unstructured":"Claveau J-S, Wetter DA, Kumar S. Cutaneous manifestations of monoclonal gammopathy. Blood Cancer J. 2022;12:58.","journal-title":"Blood Cancer J"},{"key":"1528_CR42","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1182\/blood.2020005674","volume":"136","author":"S Berentsen","year":"2020","unstructured":"Berentsen S, Barcellini W, D\u2019Sa S, Randen U, Tvedt THA, Fattizzo B, et al. Cold agglutinin disease revisited: a multinational, observational study of 232 patients. Blood. 2020;136:480\u20138.","journal-title":"Blood"},{"key":"1528_CR43","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1182\/blood-2013-02-474437","volume":"122","author":"PL Swiecicki","year":"2013","unstructured":"Swiecicki PL, Hegerova LT, Gertz MA. Cold agglutinin disease. Blood. 2013;122:1114\u201321.","journal-title":"Blood"},{"key":"1528_CR44","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3390\/hemato3040040","volume":"3","author":"S Berentsen","year":"2022","unstructured":"Berentsen S, D\u2019Sa S, Randen U, Ma\u0142ecka A, Vos JMI. Cold agglutinin disease: improved understanding of pathogenesis helps define targets for therapy. Hemato. 2022;3:574\u201394.","journal-title":"Hemato"},{"key":"1528_CR45","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1182\/hematology.2024000572","volume":"2024","author":"D Iberri","year":"2024","unstructured":"Iberri D, Liedtke M. MGCS: where do we stand today? Hematol Am Soc Hematol Educ Program. 2024;2024:482\u20138.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"1528_CR46","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1056\/NEJMoa2027760","volume":"384","author":"A R\u00f6th","year":"2021","unstructured":"R\u00f6th A, Barcellini W, D\u2019Sa S, Miyakawa Y, Broome CM, Michel M, et al. Sutimlimab in cold agglutinin disease. N Engl J Med. 2021;384:1323\u201334.","journal-title":"N Engl J Med"},{"key":"1528_CR47","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1055\/s-0037-1619606","volume":"24","author":"AB Federici","year":"2004","unstructured":"Federici AB, Budde U, Rand JH. Acquired von Willebrand syndrome 2004: International Registry\u2013diagnosis and management from online to bedside. Hamostaseologie. 2004;24:50\u20135.","journal-title":"Hamostaseologie"},{"key":"1528_CR48","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1182\/blood.V66.3.562.562","volume":"66","author":"WA Fricke","year":"1985","unstructured":"Fricke WA, Brinkhous KM, Garris JB, Roberts HR. Comparison of inhibitory and binding characteristics of an antibody causing acquired von Willebrand syndrome: an assay for von Willebrand factor binding by antibody. Blood. 1985;66:562\u20139.","journal-title":"Blood"},{"key":"1528_CR49","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/ajh.2830090403","volume":"9","author":"TE Gan","year":"1980","unstructured":"Gan TE, Sawers RJ, Koutts J. Pathogenesis of antibody-induced acquired von Willebrand Syndrome. Am J Hematol. 1980;9:363\u201371.","journal-title":"Am J Hematol"},{"key":"1528_CR50","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.3324\/haematol.2020.255117","volume":"105","author":"M Franchini","year":"2020","unstructured":"Franchini M, Mannucci PM. Acquired von Willebrand syndrome: focused for hematologists. Haematologica. 2020;105:2032\u20137.","journal-title":"Haematologica"},{"key":"1528_CR51","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/rth2.12481","volume":"5","author":"MY Abou-Ismail","year":"2021","unstructured":"Abou-Ismail MY, Rodgers GM, Bray PF, Lim MY. Acquired von Willebrand syndrome in monoclonal gammopathy - A scoping review on hemostatic management. Res Pract Thromb Haemost. 2021;5:356\u201365.","journal-title":"Res Pract Thromb Haemost"},{"key":"1528_CR52","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1182\/blood.2022018797","volume":"141","author":"AJ Kanack","year":"2023","unstructured":"Kanack AJ, Schaefer JK, Sridharan M, Splinter NP, Kohlhagen MC, Singh B, et al. Monoclonal gammopathy of thrombotic\/thrombocytopenic significance. Blood. 2023;141:1772\u20136.","journal-title":"Blood"},{"key":"1528_CR53","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1056\/NEJMoa2415930","volume":"392","author":"JJ Wang","year":"2025","unstructured":"Wang JJ, Warkentin TE, Sch\u00f6nborn L, Wheeler MB, Geerts WH, Costedoat-Chalumeau N, et al. VITT-like monoclonal gammopathy of thrombotic significance. N Engl J Med. 2025;392:995\u20131005.","journal-title":"N Engl J Med"},{"key":"1528_CR54","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1056\/NEJMc2406453","volume":"391","author":"G Salmasi","year":"2024","unstructured":"Salmasi G, Murray DL, Padmanabhan A. Myeloma therapy for monoclonal gammopathy of thrombotic significance. N Engl J Med. 2024;391:570\u20131.","journal-title":"N Engl J Med"},{"key":"1528_CR55","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1177\/11206721231155974","volume":"33","author":"RB Singh","year":"2023","unstructured":"Singh RB, Singhal S, Sinha S, Cho J, Nguyen AX-L, Dhingra LS, et al. Ocular complications of plasma cell dyscrasias. Eur J Ophthalmol. 2023;33:1786\u2013800.","journal-title":"Eur J Ophthalmol"},{"key":"1528_CR56","doi-asserted-by":"publisher","first-page":"100471","DOI":"10.1016\/j.ajoc.2019.100471","volume":"15","author":"S Karakus","year":"2019","unstructured":"Karakus S, Gottsch JD, Caturegli P, Eghrari AO. Monoclonal gammopathy of \u201cocular\u201d significance. Am J Ophthalmol Case Rep. 2019;15:100471.","journal-title":"Am J Ophthalmol Case Rep"},{"key":"1528_CR57","doi-asserted-by":"crossref","unstructured":"R\u00edos-Tamayo R, Paiva B, Lahuerta JJ, L\u00f3pez JM, Duarte RF Monoclonal gammopathies of clinical significance: A critical appraisal. Cancers. 2022;14:5247.","DOI":"10.3390\/cancers14215247"},{"key":"1528_CR58","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1080\/10428194.2021.2008385","volume":"63","author":"L Garderet","year":"2022","unstructured":"Garderet L, Al Hariri M, Wasielica-Poslednik J, Munder M, Korm\u00e1nyos K, Pena C, et al. Monoclonal gammopathy of ocular significance (MGOS) - a short survey of corneal manifestations and treatment outcomes. Leuk Lymphoma. 2022;63:984\u201390.","journal-title":"Leuk Lymphoma"},{"key":"1528_CR59","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/ajh.26240","volume":"96","author":"A Dispenzieri","year":"2021","unstructured":"Dispenzieri A. POEMS syndrome: 2021 Update on diagnosis, risk-stratification, and management. Am J Hematol. 2021;96:872\u201388.","journal-title":"Am J Hematol"},{"key":"1528_CR60","doi-asserted-by":"crossref","unstructured":"Visentin A, Pravato S, Castellani F, Campagnolo M, Angotzi F, Cavarretta CA, et al. From biology to treatment of monoclonal gammopathies of neurological significance. Cancers. 2022;14:1562.","DOI":"10.3390\/cancers14061562"},{"key":"1528_CR61","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1046\/j.1365-2141.1999.01208.x","volume":"104","author":"J Nishi","year":"1999","unstructured":"Nishi J, Arimura K, Utsunomiya A, Yonezawa S, Kawakami K, Maeno N, et al. Expression of vascular endothelial growth factor in sera and lymph nodes of the plasma cell type of Castleman\u2019s disease. Br J Haematol. 1999;104:482\u20135.","journal-title":"Br J Haematol"},{"key":"1528_CR62","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S0140-6736(96)91261-1","volume":"347","author":"O Watanabe","year":"1996","unstructured":"Watanabe O, Arimura K, Kitajima I, Osame M, Maruyama I. Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome. Lancet. 1996;347:702.","journal-title":"Lancet"},{"key":"1528_CR63","first-page":"813","volume":"25","author":"M Soubrier","year":"1998","unstructured":"Soubrier M, Guillon R, Dubost JJ, Serre AF, Ristori JM, Boyer L, et al. Arterial obliteration in POEMS syndrome: possible role of vascular endothelial growth factor. J Rheumatol. 1998;25:813\u20135.","journal-title":"J Rheumatol"},{"key":"1528_CR64","doi-asserted-by":"publisher","first-page":"4663","DOI":"10.1182\/blood-2011-06-362392","volume":"118","author":"A D\u2019Souza","year":"2011","unstructured":"D\u2019Souza A, Hayman SR, Buadi F, Mauermann M, Lacy MQ, Gertz MA, et al. The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome. Blood. 2011;118:4663\u20135.","journal-title":"Blood"},{"key":"1528_CR65","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/s41375-025-02659-7","volume":"39","author":"J Cook","year":"2025","unstructured":"Cook J, Warsame R, Omar M, Buadi FK, Abdallah N, Dingli D, et al. Interleukin-6 is a highly prognostic biomarker for POEMS syndrome. Leukemia. 2025;39:2281\u20134.","journal-title":"Leukemia"},{"key":"1528_CR66","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1182\/blood-2012-04-423178","volume":"120","author":"A D\u2019Souza","year":"2012","unstructured":"D\u2019Souza A, Lacy M, Gertz M, Kumar S, Buadi F, Hayman S, et al. Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience. Blood. 2012;120:56\u201362.","journal-title":"Blood"},{"key":"1528_CR67","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3324\/haematol.2016.148460","volume":"102","author":"G Cook","year":"2017","unstructured":"Cook G, Iacobelli S, van Biezen A, Ziagkos D, LeBlond V, Abraham J, et al. High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation. Haematologica. 2017;102:160\u20137.","journal-title":"Haematologica"},{"key":"1528_CR68","doi-asserted-by":"publisher","first-page":"e728","DOI":"10.1097\/HS9.0000000000000728","volume":"6","author":"OG Sevindik","year":"2022","unstructured":"Sevindik OG, Mutlu YG, Aydin BB, Serin I. First-line usage of Daratumumab, Lenalidomide, Dexamethasone (DRd) Combination in a Case of Castleman Disease Variant of Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome (CD-POEMS). HemaSphere. 2022;6:e728.","journal-title":"HemaSphere"},{"key":"1528_CR69","doi-asserted-by":"publisher","first-page":"e381","DOI":"10.1097\/HS9.0000000000000381","volume":"4","author":"M Gavriatopoulou","year":"2020","unstructured":"Gavriatopoulou M, Ntanasis-Stathopoulos I, Fotiou D, Migkou M, Eleutherakis-Papaiakovou E, Kanellias N, et al. Upfront daratumumab with lenalidomide and dexamethasone for POEMS syndrome. HemaSphere. 2020;4:e381.","journal-title":"HemaSphere"},{"key":"1528_CR70","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1186\/s13256-022-03552-y","volume":"16","author":"R Taenaka","year":"2022","unstructured":"Taenaka R, Shimokawa S, Katayama A, Nagao T, Obara T, Nishimura N, et al. Successful treatment with daratumumab, lenalidomide, and dexamethasone therapy followed by autologous stem cell transplantation for newly diagnosed polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome: a case report. J Med Case Rep. 2022;16:311.","journal-title":"J Med Case Rep"},{"key":"1528_CR71","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41408-023-00859-x","volume":"13","author":"I Vaxman","year":"2023","unstructured":"Vaxman I, Kumar SK, Buadi F, Lacy MQ, Dingli D, Hayman S, et al. Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience. Blood Cancer J. 2023;13:91.","journal-title":"Blood Cancer J"},{"key":"1528_CR72","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.clml.2023.04.008","volume":"23","author":"A Jurczyszyn","year":"2023","unstructured":"Jurczyszyn A, Olszewska-Szopa M, Vesole D. POEMS Syndrome-Clinical Picture and Management. Curr Knowl Clin Lymphoma Myeloma Leuk. 2023;23:575\u201382.","journal-title":"Curr Knowl Clin Lymphoma Myeloma Leuk"},{"key":"1528_CR73","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/s41375-024-02489-z","volume":"39","author":"K Lee","year":"2025","unstructured":"Lee K, Kourelis T, Tschautscher M, Warsame R, Buadi F, Gertz M, et al. Capillary leak phenotype as a major cause of death in patients with POEMS syndrome. Leukemia. 2025;39:703\u20139.","journal-title":"Leukemia"},{"key":"1528_CR74","doi-asserted-by":"crossref","unstructured":"Braud A, Lipsker D. Schnitzler syndrome: insights into its pathogenesis, clinical manifestations, and current management. Biomolecules. 2024;14:646.","DOI":"10.3390\/biom14060646"},{"key":"1528_CR75","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/all.13035","volume":"72","author":"L Gusdorf","year":"2017","unstructured":"Gusdorf L, Asli B, Barbarot S, N\u00e9el A, Masseau A, Pu\u00e9chal X, et al. Schnitzler syndrome: validation and applicability of diagnostic criteria in real-life patients. Allergy. 2017;72:177\u201382.","journal-title":"Allergy"},{"key":"1528_CR76","doi-asserted-by":"publisher","DOI":"10.1186\/2045-7022-4-41","volume":"4","author":"HD de Koning","year":"2014","unstructured":"de Koning HD. Schnitzler\u2019s syndrome: lessons from 281 cases. Clin Transl Allergy. 2014;4:41.","journal-title":"Clin Transl Allergy"},{"key":"1528_CR77","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/all.12129","volume":"68","author":"A Simon","year":"2013","unstructured":"Simon A, Asli B, Braun-Falco M, De Koning H, Fermand JP, Grattan C, et al. Schnitzler\u2019s syndrome: diagnosis, treatment, and follow-up. Allergy. 2013;68:562\u20138.","journal-title":"Allergy"},{"key":"1528_CR78","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1111\/j.1398-9995.2012.02843.x","volume":"67","author":"K Krause","year":"2012","unstructured":"Krause K, Weller K, Stefaniak R, Wittkowski H, Altrichter S, Siebenhaar F, et al. Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study. Allergy. 2012;67:943\u201350.","journal-title":"Allergy"},{"key":"1528_CR79","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.jaci.2019.12.909","volume":"145","author":"K Krause","year":"2020","unstructured":"Krause K, Bonnekoh H, Ellrich A, Tsianakas A, Wagner N, Fischer J, et al. Long-term efficacy of canakinumab in the treatment of Schnitzler syndrome. J Allergy Clin Immunol. 2020;145:1681\u2013e5.","journal-title":"J Allergy Clin Immunol"},{"key":"1528_CR80","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1182\/blood-2018-01-824862","volume":"131","author":"G Palladini","year":"2018","unstructured":"Palladini G, Merlini G. The elusive pathogenesis of Schnitzler syndrome. Blood. 2018;131:944\u20136.","journal-title":"Blood"},{"key":"1528_CR81","first-page":"182","volume":"158","author":"K Claes","year":"2008","unstructured":"Claes K, Bammens B, Delforge M, Evenepoel P, Kuypers D, Vanrenterghem Y. Another devastating complication of the Schnitzler syndrome: AA amyloidosis. Br J Dermatol. 2008;158:182\u20134.","journal-title":"Br J Dermatol"},{"key":"1528_CR82","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41572-018-0009-4","volume":"4","author":"D Roccatello","year":"2018","unstructured":"Roccatello D, Saadoun D, Ramos-Casals M, Tzioufas AG, Fervenza FC, Cacoub P, et al. Cryoglobulinaemia. Nat Rev Dis Prim. 2018;4:11.","journal-title":"Nat Rev Dis Prim"},{"key":"1528_CR83","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.jbspin.2019.01.016","volume":"86","author":"AC Desbois","year":"2019","unstructured":"Desbois AC, Cacoub P, Saadoun D. Cryoglobulinemia: An update in 2019. Jt Bone Spine. 2019;86:707\u201313.","journal-title":"Jt Bone Spine"},{"key":"1528_CR84","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/MD.0b013e318288925c","volume":"92","author":"B Terrier","year":"2013","unstructured":"Terrier B, Karras A, Kahn J-E, Le Guenno G, Marie I, Benarous L, et al. The spectrum of type I cryoglobulinemia vasculitis: new insights based on 64 cases. Medicine. 2013;92:61\u20138.","journal-title":"Medicine"},{"key":"1528_CR85","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/bjh.13196","volume":"168","author":"S Harel","year":"2015","unstructured":"Harel S, Mohr M, Jahn I, Aucouturier F, Galicier L, Asli B, et al. Clinico-biological characteristics and treatment of type I monoclonal cryoglobulinaemia: a study of 64 cases. Br J Haematol. 2015;168:671\u20138.","journal-title":"Br J Haematol"},{"key":"1528_CR86","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1056\/NEJMc1106670","volume":"365","author":"DB Sykes","year":"2011","unstructured":"Sykes DB, Schroyens W, O\u2019Connell C. The TEMPI syndrome \u2014 A novel multisystem disease. N Engl J Med. 2011;365:475\u20137.","journal-title":"N Engl J Med"},{"key":"1528_CR87","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1182\/blood.2019004216","volume":"135","author":"DB Sykes","year":"2020","unstructured":"Sykes DB, O\u2019Connell C, Schroyens W. The TEMPI syndrome. Blood. 2020;135:1199\u2013203.","journal-title":"Blood"},{"key":"1528_CR88","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.clml.2018.07.284","volume":"18","author":"X Zhang","year":"2018","unstructured":"Zhang X, Fang M. TEMPI syndrome: erythrocytosis in plasma cell dyscrasia. Clin Lymphoma Myeloma Leuk. 2018;18:724\u201330.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1528_CR89","doi-asserted-by":"publisher","first-page":"886961","DOI":"10.3389\/fendo.2022.886961","volume":"13","author":"J Xu","year":"2022","unstructured":"Xu J, Liu W, Fan F, Zhang B, Zhao F, Hu Y, et al. TEMPI syndrome: update on clinical features, management, and pathogenesis. Front Endocrinol. 2022;13:886961.","journal-title":"Front Endocrinol"},{"key":"1528_CR90","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1182\/bloodadvances.2020003783","volume":"5","author":"C Sun","year":"2021","unstructured":"Sun C, Xu J, Zhang B, Huang H, Chen L, Yan H, et al. Whole-genome sequencing suggests a role of MIF in the pathophysiology of TEMPI syndrome. Blood Adv. 2021;5:2563\u20138.","journal-title":"Blood Adv"},{"key":"1528_CR91","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1038\/leu.2015.298","volume":"29","author":"SS Kenderian","year":"2015","unstructured":"Kenderian SS, Rosado FG, Sykes DB, Hoyer JD, Lacy MQ. Long-term complete clinical and hematological responses of the TEMPI syndrome after autologous stem cell transplantation. Leukemia. 2015;29:2414\u20136.","journal-title":"Leukemia"},{"key":"1528_CR92","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1007\/s00277-019-03761-4","volume":"98","author":"S-H Liang","year":"2019","unstructured":"Liang S-H, Yeh S-P. Relapsed multiple myeloma as TEMPI syndrome with good response to salvage lenalidomide and dexamethasone. Ann Hematol. 2019;98:2447\u201350.","journal-title":"Ann Hematol"},{"key":"1528_CR93","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1056\/NEJMc1804415","volume":"378","author":"DB Sykes","year":"2018","unstructured":"Sykes DB, Schroyens W. Complete responses in the TEMPI syndrome after treatment with Daratumumab. N Engl J Med. 2018;378:2240\u20132.","journal-title":"N Engl J Med"},{"key":"1528_CR94","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1056\/NEJMc1205806","volume":"367","author":"W Schroyens","year":"2012","unstructured":"Schroyens W, O\u2019Connell C, Sykes DB. Complete and partial responses of the TEMPI syndrome to bortezomib. N Engl J Med. 2012;367:778\u201380.","journal-title":"N Engl J Med"},{"key":"1528_CR95","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/00005792-200301000-00005","volume":"82","author":"D Lipsker","year":"2003","unstructured":"Lipsker D, Rondeau M, Massard G, Grosshans E. The AESOP (adenopathy and extensive skin patch overlying a plasmacytoma) syndrome: report of 4 cases of a new syndrome revealing POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) syndrome at a curable stage. Medicine. 2003;82:51\u20139.","journal-title":"Medicine"},{"key":"1528_CR96","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.clindermatol.2020.10.002","volume":"39","author":"C Lenormand","year":"2021","unstructured":"Lenormand C, Marzolf G, Lipsker D. AESOP syndrome: a potential life-saving and early clue to the diagnosis of POEMS syndrome. Clin Dermatol. 2021;39:215\u20139.","journal-title":"Clin Dermatol"},{"key":"1528_CR97","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s00277-023-05465-2","volume":"103","author":"W Yan","year":"2024","unstructured":"Yan W, Lv R, Xu J, Li L, Cui J, Liu Y, et al. Adenopathy and extensive skin patch overlying a plasmacytoma (AESOP) syndrome: a case report and literature review. Ann Hematol. 2024;103:339\u201341.","journal-title":"Ann Hematol"},{"key":"1528_CR98","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41572-024-00571-5","volume":"10","author":"KM Druey","year":"2024","unstructured":"Druey KM, Arnaud L, Parikh SM. Systemic capillary leak syndrome. Nat Rev Dis Prim. 2024;10:86.","journal-title":"Nat Rev Dis Prim"},{"key":"1528_CR99","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/SHK.0000000000001254","volume":"52","author":"R Pierce","year":"2019","unstructured":"Pierce R, Ji W, Chan EC, Xie Z, Long LM, Khokha M, et al. Whole-exome sequencing of adult and pediatric cohorts of the rare vascular disorder systemic capillary leak syndrome. Shock. 2019;52:183\u201390.","journal-title":"Shock"},{"key":"1528_CR100","doi-asserted-by":"crossref","unstructured":"Xie Z, Nagarajan V, Sturdevant DE, Iwaki S, Chan E, Wisch L, et al. Genome-wide SNP analysis of the Systemic Capillary Leak Syndrome (Clarkson disease). Rare Dis. 2013;1.","DOI":"10.4161\/rdis.27445"},{"key":"1528_CR101","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1172\/JCI169137","volume":"134","author":"AJ Ablooglu","year":"2024","unstructured":"Ablooglu AJ, Chen W-S, Xie Z, Desai A, Paul S, Lack JB, et al. Intrinsic endothelial hyperresponsiveness to inflammatory mediators drives acute episodes in models of Clarkson disease. J Clin Invest. 2024;134:10.","journal-title":"J Clin Invest"},{"key":"1528_CR102","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s42003-019-0647-4","volume":"2","author":"A Raza","year":"2019","unstructured":"Raza A, Xie Z, Chan EC, Chen W-S, Scott LM, Robin Eisch A, et al. A natural mouse model reveals genetic determinants of systemic capillary leak syndrome (Clarkson disease). Commun Biol. 2019;2:398.","journal-title":"Commun Biol"},{"key":"1528_CR103","doi-asserted-by":"publisher","first-page":"464","DOI":"10.7326\/0003-4819-154-7-201104050-00004","volume":"154","author":"M Gousseff","year":"2011","unstructured":"Gousseff M, Arnaud L, Lambert M, Hot A, Hamidou M, Duhaut P, et al. The systemic capillary leak syndrome: a case series of 28 patients from a European registry. Ann Intern Med. 2011;154:464\u201371.","journal-title":"Ann Intern Med"},{"key":"1528_CR104","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/14779072.2018.1456920","volume":"16","author":"NU-A Baloch","year":"2018","unstructured":"Baloch NU-A, Bikak M, Rehman A, Rahman O. Recognition and management of idiopathic systemic capillary leak syndrome: an evidence-based review. Expert Rev Cardiovasc Ther. 2018;16:331\u201340.","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"1528_CR105","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s11739-019-02144-x","volume":"15","author":"M Pineton de Chambrun","year":"2020","unstructured":"Pineton de Chambrun M, Mathian A, Combes A, Luyt C-E, Amoura Z. Handling shock in idiopathic systemic capillary leak syndrome (Clarkson\u2019s disease): less is more. Intern Emerg Med. 2020;15:347\u20138.","journal-title":"Intern Emerg Med"},{"key":"1528_CR106","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1097\/CCM.0b013e31817d7c71","volume":"36","author":"M Lambert","year":"2008","unstructured":"Lambert M, Launay D, Hachulla E, Morell-Dubois S, Soland V, Queyrel V, et al. High-dose intravenous immunoglobulins dramatically reverse systemic capillary leak syndrome. Crit Care Med. 2008;36:2184\u20137.","journal-title":"Crit Care Med"},{"key":"1528_CR107","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1055\/s-0037-1607342","volume":"7","author":"ASE Asmundsson","year":"2018","unstructured":"Asmundsson ASE, Bjorklund AR, Fisher GA. Diagnosis of systemic capillary leak syndrome in a young child treated with intravenous immunoglobulin in the acute phase. J Pediatr Intensive Care. 2018;7:94\u20136.","journal-title":"J Pediatr Intensive Care"},{"key":"1528_CR108","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.amjmed.2014.08.015","volume":"128","author":"Z Xie","year":"2015","unstructured":"Xie Z, Chan EC, Long LM, Nelson C, Druey KM. High-dose intravenous immunoglobulin therapy for systemic capillary leak syndrome (Clarkson disease). Am J Med. 2015;128:91\u20135.","journal-title":"Am J Med"},{"key":"1528_CR109","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1016\/j.jaip.2022.07.006","volume":"10","author":"Q Moyon","year":"2022","unstructured":"Moyon Q, Pineton de Chambrun M, Gousseff M, Mathian A, Hie M, Urbanski G, et al. Intravenous immunoglobulins tapering and withdrawal in systemic capillary leak syndrome (Clarkson disease). J Allergy Clin Immunol Pr. 2022;10:2889\u201395.","journal-title":"J Allergy Clin Immunol Pr"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01528-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01528-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01528-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:09:10Z","timestamp":1785456550000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01528-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":109,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1528"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01528-5","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"10 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SVR is Chair of the International Myeloma Foundation Board of Directors; has received honoraria for CME Lectures for Medscape; declares intellectual property and royalties as an author and section editor for UpToDate (covering topics on plasma cell disorders). SK has acted as a consultant or adviser (with all payments made to his institution) for AbbVie, Bristol Myers Squibb\/Celgene, Genentech\/Roche, Janssen Oncology\/Johnson & Johnson, K36, Pfizer, Regeneron, Sanofi and Takeda; declares research funding (to his institution) from AbbVie, Allogene Therapeutics, Bristol Myers Squibb\/Celgene, CARsgen Therapeutics, GlaxoSmithKline, Janssen Oncology\/Johnson & Johnson, MedImmune, Novartis, Regeneron, Roche\/Genentech, Sanofi and Takeda; and has received reimbursement for travel, accommodation and expenses from AbbVie, Beigene, Janssen\/Johnson & Johnson and Pfizer. MSS declares no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"128"}}